Related Experiment Video

Updated: Dec 21, 2025

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.4K

Overcoming Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutated Tumours

Emily L Paton1, Jacqueline A Turner1, Isabel R Schlaepfer1

  • 1Division of Medical Oncology, The University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA.

Journal of Oncology
|May 16, 2020
PubMed

Insights

MAPK pathway overactivation drives cancer, but BRAF/MEK inhibitors face resistance. This review explores resistance mechanisms and novel preclinical strategies like apoptosis induction and metabolic targeting to improve cancer therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Mitogen-activated protein kinase (MAPK) pathway overactivation is a key driver in numerous human cancers.
  • FDA-approved BRAF and MEK inhibitors targeting MAPK signaling show variable efficacy and are often overcome by rapid drug resistance.

Purpose of the Study:

  • To review established mechanisms of resistance to MAPK-targeted therapies in BRAF-mutated cancers.
  • To discuss emerging preclinical strategies for overcoming therapeutic resistance.

Main Methods:

  • Literature review of preclinical studies on MAPK pathway inhibitors.
  • Analysis of resistance mechanisms in BRAF-mutated cancers.
  • Synthesis of novel therapeutic approaches targeting resistance.

Main Results:

  • Identified key resistance mechanisms to current MAPK inhibitors.
  • Highlighted preclinical strategies including apoptosis promotion, autophagy modulation, and mitochondrial metabolism targeting.
  • Demonstrated potential for novel therapeutic combinations.

Conclusions:

  • Understanding MAPK inhibitor resistance is crucial for developing effective cancer treatments.
  • Preclinical strategies targeting apoptosis, autophagy, and metabolism offer promising avenues to overcome resistance.
  • Further research into novel therapeutic combinations is warranted to improve patient outcomes in BRAF-mutated cancers.

More Related Videos

A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.4K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.1K

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K